Apellis Pharmaceuticals (NASDAQ:APLS) Lowered to Neutral Rating by Bank of America
Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) was downgraded by investment analysts at Bank of America from a “buy” rating to a “neutral” rating in a research note issued to investors on Friday, Marketbeat Ratings reports. They currently have a $23.00 target price on the stock, down from their previous target price of $41.00. Bank […]
Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) was downgraded by investment analysts at Bank of America from a “buy” rating to a “neutral” rating in a research note issued to investors on Friday, Marketbeat Ratings reports. They currently have a $23.00 target price on the stock, down from their previous target price of $41.00. Bank […]
